All News

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/nivolumab combination regimen, 3 had remission beyond 2 years.

Data from the LITESPARK-015 trial supported the FDA’s decision to approve belzutifan monotherapy in patients with advanced, unresectable, or metastatic PPGL.

The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.

AI has the potential to change practice patterns, improve imaging, and inform treatment planning for patients with brain tumors.

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for maximizing safe resection in newly diagnosed high-grade gliomas.

Oncology clinicians can effectively collaborate with neuroradiologists using advanced techniques to improve brain tumor characterization.

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.

Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress.

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.

Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.

Nicholas Blondin, MD, discusses the latest advancements in immunotherapy for brain cancer as well as emerging strategies, including CAR T-cell therapy.

Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.

An independent data safety monitoring board determines that the phase 2b SURVIVE trial in newly diagnosed glioblastoma may continue without modification.

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.

At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.

Policy changes supporting breastfeeding may address structural barriers and lower overall incidence and racial disparities surrounding TNBC in the US.

Joseph C. Landolfi, DO, CPE, and Michele Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.